Q32 Bio Inc. (QTTB) — 8-K Filings

8-K Filings (20)

• 8-K Filing — May 5, 2026
• 8-K Filing — Dec 19, 2025
• 8-K Filing — Dec 1, 2025
• Q32 Bio Inc. Files 8-K Report — Nov 13, 2025 Risk: medium
  On November 13, 2025, Q32 Bio Inc. filed an 8-K report. The filing indicates a change in the company's status or operations, though specific details regarding f
• Q32 Bio Files 8-K Report — Oct 21, 2025 Risk: low
  On October 21, 2025, Q32 Bio Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The company, former
• Q32 Bio Inc. Announces Executive Changes and Filings — Jun 25, 2025 Risk: medium
  On June 20, 2025, Q32 Bio Inc. filed an 8-K report detailing several key events. The company announced the departure of Director Dr. Elias P. Rosenblatt and the
• Q32 Bio Inc. Files 8-K on Security Holder Rights & Bylaws — Jun 17, 2025 Risk: medium
  Q32 Bio Inc. filed an 8-K on June 17, 2025, reporting material modifications to security holder rights, amendments to its articles of incorporation, and the sub
• Q32 Bio Inc. Faces Delisting or Listing Transfer — May 23, 2025 Risk: high
  Q32 Bio Inc. filed an 8-K on May 23, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of listing
• Q32 Bio Inc. Files 8-K: Leadership and Compensation Updates — Apr 25, 2025 Risk: medium
  On April 25, 2025, Q32 Bio Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a shift in lead
• Q32 Bio Regains ADG885 Rights from BMS — Mar 10, 2025 Risk: medium
  On March 8, 2025, Q32 Bio Inc. filed an 8-K report to announce the termination of its collaboration and license agreement with Bristol-Myers Squibb Company. The
• Q32 Bio Inc. Files 8-K on Exit Activities — Feb 10, 2025 Risk: medium
  Q32 Bio Inc. filed an 8-K on February 10, 2025, reporting on cost-associated exit or disposal activities, Regulation FD disclosures, and financial statements/ex
• 8-K Filing — Jan 13, 2025
• Q32 Bio Inc. Files 8-K for December 10, 2024 Events — Dec 11, 2024 Risk: low
  Q32 Bio Inc. filed an 8-K on December 11, 2024, reporting on events that occurred on December 10, 2024. The filing primarily concerns Regulation FD Disclosure,
• Q32 Bio Inc. Completes Merger with Cache Acquisition Corp. — Jul 9, 2024 Risk: medium
  On July 9, 2024, Q32 Bio Inc. filed an 8-K to report on the completion of its previously announced merger with Cache Acquisition Corp. The merger was approved b
• Sanofi Acquires Q32 Bio Inc. — Mar 27, 2024 Risk: medium
  Q32 Bio Inc. announced on March 25, 2024, the completion of its acquisition by a subsidiary of Sanofi. The transaction was approved by Q32 Bio's stockholders on
• Axsome to Acquire Homology Medicines for $1.1B — Mar 20, 2024 Risk: medium
  Homology Medicines, Inc. announced on March 20, 2024, that it has entered into a definitive agreement to be acquired by Axsome Therapeutics, Inc. The transactio
• Homology Medicines Reports on Shareholder Vote Matters — Mar 15, 2024 Risk: low
  Homology Medicines, Inc. filed an 8-K on March 15, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific
• Homology Medicines Acquired by — Mar 11, 2024 Risk: medium
  Homology Medicines, Inc. announced on March 11, 2024, that it has entered into a definitive agreement to be acquired by''. The transaction is expected to close
• Homology Medicines Files 8-K for Rule 425 Communications — Jan 26, 2024
  Homology Medicines, Inc. filed an 8-K on January 26, 2024, indicating that it is providing written communications pursuant to Rule 425 under the Securities Act.
• Homology Medicines Faces Nasdaq Delisting Notice — Jan 3, 2024
  Homology Medicines, Inc. (FIXX) filed an 8-K on January 3, 2024, reporting an event on December 29, 2023, related to a notice of delisting or failure to satisfy

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX